Navigation Links
Diamyd(R) Phase III Study Approved for Younger Patients in the US
Date:6/8/2009

STOCKHOLM, June 8 /PRNewswire-FirstCall/ -- Diamyd Medical reported today that the company has received approval from the US Food and Drug Administration (FDA) to include children with type 1 diabetes from 10 years of age in the company's Phase III study with the diabetes vaccine Diamyd(R).

(Logo: http://www.newscom.com/cgi-bin/prnh/20080314/297194 )

Diamyd Medical is conducting two parallel phase III studies, one in Europe and one in the USA, comprising a total of 640 patients. The objective of the studies is to evaluate the ability of the Diamyd(R) vaccine to halt or delay the autoimmune attack on the body's insulin-producing cells, thereby preserving the body's own ability to produce insulin in children and adolescents with recent-onset type 1 diabetes.

The European study, which is being conducted in nine countries, is approved for patients between 10 and 20 years of age, whilst the US study so far has been approved only for patients 16 to 20 years, an age group with few recent-onset type 1 diabetes patients. The company is, with the new approval, allowed to begin enrollment of children from 10 years of age in the US phase III study.

"This is a big step forward giving us the opportunity to accelerate patient recruitment in the US," says Elisabeth Lindner, President and CEO of Diamyd Medical. "We are pleased that the approval comes now in connection with the world's largest diabetes conference, the ADA's 69th Scientific Sessions, which is currently ongoing in New Orleans."

The company will now, in pace with Institutional Review Board (IRB) approvals in USA, increase the number of American pediatric clinics in the study. The application for market approval is, as before, planned for spring 2011.

Diamyd Medical is represented at booth #2431 at the ADA's 69th Scientific Se
'/>"/>

SOURCE Diamyd Medical AB (publ)
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. D-Pharm Receives FDA Clearance to Commence a Phase III Trial of DP-b99 in Acute Stroke Patients
2. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
3. Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis
4. Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
5. Mersana Reports Preliminary Phase 1 Results of XMT-1001 in Patients with Advanced Solid Tumors
6. Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study
7. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting
8. Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel
9. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
10. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
11. Oral VDA CYT997 - Phase I Clinical Trial Presentation at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... July 29, 2014 Human Longevity, Inc. (HLI), ... focused on extending the healthy, high performance human life ... , Ph.D., an expert in machine learning and machine ... to HLI from Google where he was Distinguished Research ... report directly to HLI Co-Founder and CEO, J. ...
(Date:7/29/2014)... , July 29, 2014  Pomerantz LLP is ... Inc. ("Impax" or the "Company") (NASDAQ: IPXL).  Such investors ... at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. ... its officers and/or directors have violated Sections 10(b) and ... On July 29, 2014, Impax Laboratories, Inc. ...
(Date:7/29/2014)... PORTLAND, Oregon , July 29, 2014 ... titled, "Global surgical equipment market (types, applications and geography) ... Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - ... expected to reach $12.1 billion by 2020 registering a ... Due to the breakthrough achieved by the electro surgical ...
(Date:7/29/2014)... Philadelphia’s newest entrepreneurial incubation space is ready for business, and ... Center @3401 , a collaborative effort of Drexel University ... help attract and nurture start-up businesses in the region, officially ... , The Innovation Center @3401 (ic@3401), which is located at ... home of DreamIt Ventures and Point.io ...
Breaking Biology Technology:Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 2Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 3SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Impax Laboratories, Inc. - IPXL 2Global Surgical Equipment Market is expected to reach $12.1 billion by 2020 - Allied Market Research 2Global Surgical Equipment Market is expected to reach $12.1 billion by 2020 - Allied Market Research 3Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 2Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 3
... Research Foundation has licensed the California immunological research ... WARF's stem cell patents, Chemicon's parent company Serologicals ... to WARF's portfolio of stem cell technologies, which were ... . , ,Jeff Linton, president of Chemicon, said ...
... Platypus Technologies of suburban Madison has received ... for $200,000 from the National Cancer Institute. The grant ... rapid quantification of protein activity, useful for cancer research. ... II SBIR grant for $2.14 million from the National ...
... Customer Potential Management , a developer of databases and ... management solution has been implemented at the Michigan hospital ... the CRM solution to promote its collaboration with the ... with oncologists from both hospitals. While market research said ...
Cached Biology Technology:WARF signs stem cell agreement with California firm 2
(Date:7/28/2014)... the U.S. Food and Drug Administration (FDA) for other ... pathogens inside human cells, including those that cause Legionnaires, ... in mBio , the online open-access journal of ... of identifying non-antibiotic drugs that could one day help ... on the list inhibit the growth of at least ...
(Date:7/28/2014)... States have a circulatory problem of the legs called ... even require surgery in serious cases. This disease can ... limb amputation. , At The University of Texas Health ... a non-surgical preventative treatment in a mouse model of ... circulation. Their proof-of-concept study appears in the journal ...
(Date:7/28/2014)... rat brain cells suggests that the effects of a ... cells are temporary. , The study, published in this ... was conducted by biologists at the University of California, ... York in response to concerns, arising from multiple studies ... to general anesthetics may increase their susceptibility to long-term ...
Breaking Biology News(10 mins):New route to identify drugs that can fight bacterial infections 2Scientists discover genetic switch that can prevent peripheral vascular disease in mice 2Study suggests disruptive effects of anesthesia on brain cell connections are temporary 2Study suggests disruptive effects of anesthesia on brain cell connections are temporary 3
... genomics initiative ever undertaken an international effort to ... Earth will be officially activated this week. , ... launched by the Minister of Research and Innovation, Glen ... Saturday, September 25 at 6:30 p.m. , By enabling ...
... Contrary to a thousand face cream adverts, the secret of ... Dr. Carlos Herrera, a Professor of Research at the Consejo ... the withering action of flowers may have evolved to protect ... issue of the Annals of Botany ( http://dx.doi.org/10.1093/aob/mcq160 ...
... objects in a new computer program designed to give people ... thought the ease of the using the program,s automatic mode ... many participants in a pilot study didn,t like it because ... mode, which requires them to think several steps ahead and ...
Cached Biology News:Building a digital library for life on Earth 2Robotic arm's big flaw: Patients say it's 'too easy' 2
... This CLS number is a ... easily match Cornings product number. ... please order under the old ... customer service for assistance. ...
... Maximize the value of your microarray data ... support you need from consultation to extensive ... date methods. Utilize our expertise in combination ... from your own microarray experiments., ,Normalization and ...
BD Falcon 850 cm Smooth-surface TufRol Roller Bottle, tissue-culture treated polystyrene, blow-molded one-piece design, with easy on/off non-vented cap. (2/sp, 20/ca) Packaging: 2 / pack, 20 /...
... of Flight Mass Analyzer for superior sensitivity, mass accuracy, and resolving ... m/z, * Precursor ion selection range: 150 - 4000 m/z, * ... with internal reference, * Dynamic range: 4 orders of magnitude ... ...
Biology Products: